Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Non-Current Liabilities (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Total Non-Current Liabilities data on record, last reported at $25.9 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 6.81% year-over-year to $25.9 million; the TTM value through Oct 2025 reached $25.9 million, up 6.81%, while the annual FY2025 figure was $28.5 million, 3.09% up from the prior year.
  • Total Non-Current Liabilities reached $25.9 million in Q4 2025 per CSBR's latest filing, down from $26.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $29.1 million in Q2 2023 and bottomed at $17.0 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $25.2 million, with a median of $25.9 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 44.66% in 2021, then fell 12.59% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $21.0 million in 2021, then grew by 26.57% to $26.6 million in 2022, then rose by 4.35% to $27.7 million in 2023, then dropped by 12.59% to $24.2 million in 2024, then grew by 6.81% to $25.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $25.9 million in Q4 2025, $26.9 million in Q3 2025, and $28.5 million in Q2 2025.